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Abstract: Doxorubicin is an effective chemotherapeutic drug, however, its toxicity  
is a significant limitation in therapy. Encapsulation of doxorubicin inside liposomes  
or ferritin cages decreases cardiotoxicity while maintaining anticancer potency. We synthesized 
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novel apoferritin- and liposome-encapsulated forms of doxorubicin (“Apodox” and “lip-8-dox”) 
and compared its toxicity with doxorubicin and Myocet on prostate cell lines. Three different 
prostatic cell lines PNT1A, 22Rv1, and LNCaP were chosen. The toxicity of the modified 
doxorubicin forms was compared to conventional doxorubicin using the MTT assay,  
real-time cell impedance-based cell growth method (RTCA), and flow cytometry.  
The efficiency of doxorubicin entrapment was 56% in apoferritin cages and 42% in the 
liposome carrier. The accuracy of the RTCA system was verified by flow-cytometric 
analysis of cell viability. The doxorubicin half maximal inhibition concentrations (IC50)  
were determined as 170.5, 234.0, and 169.0 nM for PNT1A, 22Rv1, and LNCaP, 
respectively by RTCA. Lip8-dox is less toxic on the non-tumor cell line PNT1A compared 
to doxorubicin, while still maintaining the toxicity to tumorous cell lines similar to 
doxorubicin or epirubicin (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for  
22Rv1 and LNCaP). Apodox IC50 was determined as follows: 603.1, 1344.2, and 931.2 nM 
for PNT1A, 22Rv1, and LNCaP. 




The anthracycline antibiotic family comprises hundreds of analogues, but only a few are in actual 
clinical use. The best known and the most widely used are doxorubicin and epirubicin. 
Doxorubicin is an effective chemotherapeutic drug in a wide range of cancers, including both 
hematological and solid tumors [1]. The therapeutic activity of doxorubicin is achieved through  
the processes of intercalating into DNA, inhibiting topoisomerase II, and preventing DNA and RNA 
synthesis [2]. 
One of the biggest hurdles encountered in cancer therapy includes the problem of dose-dependent 
toxicity toward the non-cancerous cells because high doses of drug treatment were generally required 
owing to poor drug accessibility to the tumor site. The total lifetime dose of the doxorubicin is limited 
to 550 mg/m2. As the lifetime accumulative dose approaches 500 mg/m2 and beyond, life-threatening 
cardiomyopathy becomes more likely, which can lead to dilated cardiomyopathy (DCM) and congestive 
heart failure (CHF) in up to 20% of cases [3]. It has also been shown that doxorubicin can produce acute 
toxicity due to bone marrow attenuation, alopecia and oral ulceration [4]. 
The newer anthracyclines, such as epirubicin, and idarubicin have higher lipophilicity and putatively 
greater safety. However, the risk of inducing cardiomyopathy is not abated; the median cumulative  
dose of epirubicin to the development of symptomatic CHF is 1134 mg/m2 [5]. Early studies found that 
encapsulation of doxorubicin inside liposomes decreases the cardiotoxicity associated with the free  
form of the drug, while maintaining anticancer potency [6–13]. Since the liposomal form of the drug is 
less toxic for the nondividing cells, increased drug dosages can be administered, ensuing in improved 
efficacy and an increase in the therapeutic index. Furthermore, Rahman et al. have shown that  
liposome-encapsulated doxorubicin modulates the multidrug-resistance (MDR) phenotype in cancer 
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cells by changing the function of p-glycoprotein. The liposomes bound to p-glycoprotein [14,15], which 
was associated with enhanced cellular drug accumulation and altered drug distribution inside the  
cells [14,16–18]. The modulation of MDR phenotype by liposomes has been also demonstrated in mice 
transfected with a functional human mdr-l gene [19]. 
Another promising delivery system for anticancer drugs seems to be apoferritin [20]. Apoferritin  
is the iron-free form of ferritin, a naturally-occurring iron-storage protein consisting of 24 protein 
subunits. Its protein subunits assemble to form a hollow cage into which diverse substances, such as 
drugs, can be placed. Furthermore, ferritin is internalized by some tumors, which can enable targeting 
to those tumorous tissues [20]. Using apoferritin as a nanocarrier has the potential to move undetected 
through the body without inducing any resistance from the immune system of the patient. 
An invention of a drug delivery system, which is biocompatible, stable, and non-toxic for healthy 
tissue, but still has high anticancer potency, is a great challenge in anticancer drug research. We 
synthetized novel apoferritin- and liposome-coated forms of doxorubicin (“Apodox” and “Liposome-8”) and 
compared their toxicity with doxorubicin and Myocet on prostate cell lines. Three different prostatic cell 
lines PNT1A, 22Rv1, and LNCaP were chosen as a model of prostate cancer. 
Cell line 22Rv1 is derived from a primary tumor and LNCaP represents secondary tumor derived 
from lymph node metastasis. PNT1A cells are androgen-receptor positive and express wild-type p53. 
This line was used as a representative of healthy prostatic tissue, taking into account a limitation resulting 
from faster proliferative rate of PNT1A compared with low basal proliferative rate in normal prostatic 
glands [21]. 
The point of interest of this study was to compare the toxicity of the modified doxorubicin forms  
with commercially available forms using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay, real-time cell impedance-based cell growth method, and flow cytometry. 
2. Results 
2.1. Characteristics of Modified Doxorubicin Forms 
First, we prepared encapsulated 100 µg/mL doxorubicin into 1 mg/mL liposome and 1 mg/mL of 
apoferritin as is shown in Figure 1A,B. Details of liposome and apoferritin preparation as well as 
doxorubicin encapsulation are described in caption 4.2 and 4.3. The size and zeta potential of the 
nanovesicles were measured using a zetasizer. According to the results, the light scattering measurement 
of liposome (Figure 1C) showed that the median size is 106 nm (40–250 nm) with a small population of 
liposomes of average size about 800 nm. To prove stability of liposomes, the measurement of the  
zeta potential (or charge density) was carried out. The high value of zeta potential (−54 ± 0.15 mV) 
shows high stability as a result of its permanent negative charges on the surface of liposomes. On the 
Figure 1D is microphotograph of used liposome (highlighted in circle). Subsequently, we performed  
a light scattering measurement of apoferritin (Figure 1E). Our results proved that the median size of 
particles is 10 nm (5–15 nm) which is in a good agreement with other publications [1]. High stability of 
apoferritin and its negative charge a results in a high value of zeta potential (−7.09 mV). 
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Figure 1. Scheme of encapsulation of doxorubicin into (A) the liposome modified by 
cholesterol and (B) apoferritin. (C) Size distribution of liposome and (D) microphotography 
of liposomes. Liposomes are highlighted with a circle (red circle = 100 nm and orange  
circle = 200 nm); (E) Size distribution of apoferritin. Absorbtion spectra in the range 230–800 nm 
of (F) 100 µg/mL Myocet; (G) Epirubicin; (H) Liposome (a), Doxorubicin (b), Encapsulated 
Doxorubicin into the liposome (c); (I) Apoferritin (a), Doxorubicin (b), Encapsulated 
Doxorubicin into the apoferritin (c); Emission spectra in the range 520–820 nm of (J)  
100 µg/mL Myocet; (K) Epirubicin; (L) Liposome (a), Doxorubicin (b), Encapsulated 
Doxorubicin into the liposome (c); (M) Apoferritin (a), Doxorubicin (b), Encapsulated 
Doxorubicin into the apoferritin (c). The excitation wavelength was 510 nm. 
 
Spectrophotometric characterization of epirubicin, myocet, and doxorubicin encapsulated into the 
liposome was carried out by measuring the absorbance spectra of studied variants of doxorubicin in the 
range from 230 to 800 nm of studied variants of doxorubicin. Figure 1E shows the absorbance maximum 
0.1 absorbance units (AU) of (100 µg/mL) myocet at 496 nm. Epirubicin shows higher absorption 
maximum 0.52 AU at 490 nm in comparison with myocet (Figure 1F). Subsequently, we compared  
the absorbance spectra of Liposome (a), Doxorubicin (b), and encapsulated Doxorubicin into the 
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liposome (c). The results indicate that the liposomes do not show the highest absorbance. Absorbance of 
doxorubicin 0.49 AU at 490 m is comparable with epirubicin. Absorbance of encapsulated doxorubicin 
into the liposome shows a decreasing trend with a small peak at 590 nm and with an absorbance 
maximum of 0.23 AU (Figure 1G). In addition, from the graph in Figure 1H, the low absorbance of 
apoferritin is evident. In the case of encapsulated doxorubicin into apoferritin, the absorbance maximum 
of 0.23 AU at 590 nm is higher in comparison with doxorubicin encapsulated into liposome. 
Subsequently, the fluorescence spectra of anticancer drugs in the range 520–820 nm at λ = 510 nm  
of anticancer drugs were measured. Myocet (Figure 1I) shows the fluorescence maximum of 9654 AU 
at 596 nm, while this value for epirubicin is 75,675 AU at 596 nm, representing an 87% decrease  
of fluorescence caused by encapsulation of anticancer drug into the liposome. The same trend  
was estimated for doxorubicin and liposomal doxorubicin. The liposome alone does not have any 
fluorescence properties, after encapsulation of doxorubicin there is an increase of fluorescence to  
22,686 AU at 596 nm what is in comparison with doxorubicin alone enhancement by 70%. In the case 
of apoferritin encapsulated doxorubicin (27,601 AU at 596 nm), the absorbance is decreaseing by 63% 
in comparison with doxorubicin and apoferritin showing no fluorescence. From obtained results  
we estimated the total 72.4 µM (42 µg/mL) doxorubicin was encapsulated into the total amount of 20 mg 
of liposome carriers. Consequently, cholesterol content was quantified in liposomal particles. Total  
0.1 µg/mL was determined. Thus, the prepared liposomes contained 210 µg of doxorubicin per 
micromole of cholesterol. With regard to apodox, 56 µg/mL of doxorubicin (96.5 µM) was encapsulated 
into apoferritin cages. Final concentration of apoferritin was 1 mg/mL. Initial concentration of doxorubicin 
was 100 µg/mL (172.4 µM) in both cases. It follows that the efficiency of doxorubicin entrapment was 
42% in case of liposome carrier and 56% in case of apoferritin. 
2.2. Stability of Nanocarriers 
We determined doxorubicin in concentration range from 0 to 2 mM in solutions of various 
concentration of serum (in PBS), Figure 2A. We choose 5% serum phosphate buffer as a model condition 
for the following experiment, because of sufficient sensitivity for such determinations. Next we tested 
the stability of complex doxorubicin-liposome and doxorubicin-apoferritin in phosphate buffer pH 7.4 
(Figure 2B). Here the difference of releasing amount was obvious for both carriers. Liposome seems  
to be more sensitive to the phosphate buffer pH 7.4. Apoferritin is stable in the time period  
from 0 to 60 min. Effect of serum presence was tested in time interval from 0 to 60 min (Figure 2C). 
Here the decrease of signal observed is related to the determinations in PBS only. Change in relative 
releasing amount in apoferritin was about 2% and in liposome about 8%. Both carriers seem to be 
relatively stable in the phosphate buffer pH 7.4 with 5% serum in the time period from 0 to 60 min. 
Liposome structure was more sensitive to the presence of 5% serum phosphate buffer at pH 7.4. 
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Figure 2. (A) Calibration curves of doxorubicine determined in phosphate buffer pH 7.4 
with various content of serum as follows: (a) 0%, (b) 5%, (c) 7.5%, and (d) 10%; (B) Current 
signals of the released doxorubicin (related to the enclosed concentration) from liposome (a)  
and apoferritin (b) in phosphate buffer at pH 7.4 over a 60-min period; (C) Current signals 
of the released doxorubicin from liposome (a) and apoferritin (b) in 5% serum phosphate 
buffer at pH 7.4 over a 60-min period. Displayed as a mean ± S.E. 
 
2.3. Comparison of Toxicity of Modified Doxorubicin 
First, toxicity of the modified forms of doxorubicin was analyzed. Factorial analysis of variance 
(ANOVA) was conducted to compare the effect of modified forms of doxorubicin on prostatic cell lines, 
all other factors were adjusted. There was a significant effect of the form of doxorubicin used on  
cell lines F(4, 68) = 20.49, p < 0.0001. Post-hoc comparisons using Bonferroni test indicated the  
highest toxicity of the epirubicin and doxorubicin, with mean half-maximal lethal dose (inhibition 
concentrations, IC50) 118.0 and 268.9 nM, respectively. Toxicity of Apodox and Lip-8-dox was 
significantly lower; IC50 = 1095.0 and 1014.5 nM, respectively. Myocet showed the lowest toxicity with 
mean IC50 = 1915.4 nM (Table 1). 
Consequently, the effect of cell lines was analyzed in order to assess, if the sensitivity of individual 
cell lines to cytostatics differs significantly. After adjustment to all other variables, there was no 
significant effect of cell line, F(2, 68) = 0.46, p = 0.62 (Table 1). Despite the statistical insignificance, 
the highest sensitivity to cytostatics was observed in 22Rv1 cell line and the lowest sensitivity was 
observed in non-tumor PNT1A cell line. 
To reveal, whether this trend in cell lines is common for all cytostatics, a combined effect of cytostatics 
and cell lines was analyzed. Using this test, significant differences were observed, F(8, 68) = 3.08,  
mp = 0.005. However, the only significant trend between combined effect of cytostatics and cell lines 
was determined in Myocet; sensitivity of LNCaP cell line to this cytostatic was significantly lower 
compared to the non-tumor PNT1A cell line (IC50 = 3216.1 and 1259.9 nM, respectively). Results 
demonstrated in previous paragraphs did not take into concern type of viability assay. To check whether 
these assays provide identical results, MTT and real-time cell impedance-based cell growth method 
(RTCA) IC50 values were analyzed after adjustment of all other variables. Impedance-based RTCA IC50 
values are on average 1.6-fold lower compared to metabolic-based MTT assay, F(1, 68) = 6.48, p = 0.013, 
(Table 1). 
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Table 1. Comparison of half-maximal inhibition concentrations (IC50) for particular  
cell lines, cytostatics and used assay. S.E., standard error. Differences were considered 
significant, when p < 0.05. * Significantly different from doxorubicin (Analysis of variance 
(ANOVA) followed by Bonferroni post hoc testing) † Significantly different from epirubicin 
(ANOVA followed by Bonferroni post hoc testing) ‡ Significantly different from lip-8-dox 
(ANOVA followed by Bonferroni post hoc testing) § Significantly different from apodox 
(ANOVA followed by Bonferroni post hoc testing) ǁ Significantly different from myocet 
(ANOVA followed by Bonferroni post hoc testing) $ Significantly different from MTT 




N IC50 (Mean ± S.E.) 
Significant 
Difference  
(At p < 0.05) 
Cytostatic F(4, 68) = 20.49, p < 0.0001 
Epirubicin 21 118.0 ± 27.2 ‡, §, ǁ 
Doxorubicin 18 268.9 ± 43.6 §, ǁ 
Apodox 22 1095.0 ± 163.8 *, †, ǁ 
Lip-8 16 1014.5 ± 209.8 †, ǁ 
Myocet 21 1915.4 ± 417.3 *, †, ‡, § 
Cell line F(2, 68) = 0.46, p = 0.47 
PNT1A 36 936.3 ± 167.9  
22RV1 32 834.5 ± 161.5  
LNCaP 30 915.1 ± 299.6  
Method F(1, 68) = 6.48, p < 0.013 
MTT 31 1200.1 ± 316.1  
RTCA 67 756.1 ± 98.1 $ 
Taken together, these results suggest that doxorubicin modified by a liposome or apoferritin is less 
toxic to prostatic cell lines. The commercially available liposomal modification Myocet exhibited  
the lowest cytotoxicity among all the studied antineoplastic agents; it also showed a less toxic effect  
on LNCaP derived from the secondary site compared to non-tumor PNT1A. However, differences 
between assays were revealed, therefore, the type of the assay has to be taken into account when 
analysing the cytotoxic effects of individual doxorubicin modifications on individual cell lines. 
Therefore, detailed results of these assays were analysed separately by the assay type in the next step. 
Comparison of MTT and Real-Time Cell Impedance-Based Cell Growth Method (RTCA)  
Viability Assays 
In this step, results obtained only by MTT were analyzed. Results are not in agreement with previous 
overall results, that did not take into account viability assay, since these data do not show significant 
effect of cytostatics and cell lines on cell toxicity, F(8, 16) = 1.32, p = 0.30. 
Further, results obtained by RTCA were analyzed. The combined effect of cytostatics and cell line 
affected inhibition concentrations significantly; F(8, 52) = 2.24, p = 0.039. In contrast to MTT and 
overall results, RTCA-based results show that the Lip-8-modified form of doxorubicin is less toxic on 
the non-tumor cell line PNT1A compared to doxorubicin, while still maintaining the toxicity to tumorous cell 
lines (Table 2) (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for 22Rv1 and LNCaP). 
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To identify the relations between MTT and RTCA, Spearman correlation was calculated on mean 
IC50 values. Significant, but relatively weak positive correlation was observed (rSp = 0.48, p = 0.03).  
Taken together, since there is only the moderate correlation between methods used, the partial 
disagreement between the results of ANOVAs needs further elucidation. Therefore, the accuracy  
of the RTCA-based viability analysis was verified using another method, flow-cytometry. 
2.4. Flow-Cytometric Viability Analysis 
To assess, whether the RTCA system determines viability exactly, flow-cytometric analysis of cell 
viability (% propidium-iodide-positive, i.e., dead) was employed (Figure 3). Cell lines were treated with 
concentrations of cytostatics defined as IC50 by RTCA. Concentrations are shown on Table 2. After  
the treatment, the portion of propidium-iodide-positive cells was determined as follows: 40.14% ± 11.86%, 
38.83% ± 4.61%, and 35.97% ± 7.71% for PNT1A, 22Rv1, and LNCaP, respectively. These values  
were compared against a theoretical value of 50% using one sample t-test. None differed significantly, 
suggesting RTCA analysis accurately estimated the portion of necrotic cells (Figure 4D). 
Figure 3. Analysis of prostatic cell line growth treated with modified forms of doxorubicin 
using RTCA xCELLigence and determination of viable cell numbers by propidium iodide 
exclusion (inset). Cell lines shown in columns, modified doxorubicin forms in rows. Cell 
growth expressed as “cell index” on y-axis is based on impedance measurement. Increasing 
concentrations of antineoplastic agents in range 0–40 µM are depicted by green color 
gradient. Inset: viable cell numbers analyzed after treatment with IC50 concentrations of 
individual cytostatics on individual cell lines as determined by RTCA. FSC-A, forward 
scatter. Grey line indicate gating threshold for propidium iodide (PI)-positive (upper–left) 
and -negative cells (lower–right). Percentages in subsequent gating regions indicate number 
of PI-positive and -negative cells. 
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Table 2. Comparison of RTCA-based half-maximal concentrations (IC50). S.E., standard 
error. Differences were considered significant, when p < 0.05; * Significantly different from 
lip-8-dox PNT1A (ANOVA followed by Bonferroni post hoc testing); † Significantly 
different from myocet 22Rv1 (ANOVA followed by Bonferroni post hoc testing). 
Factor Cytostatic Cell Line N IC50 (Mean ± S.E.) Significant Difference (At p < 0.05)
F(8, 52) = 2.24,  
p < 0.039 
epirubicin 
PNT1A 3 12.2 ± 3.5 * 
22RV1 6 49.2 ± 10.5 *, † 
LNCaP 6 107.9 ± 57.0 *, † 
doxorubicin 
PNT1A 5 170.5 ± 40.0 *, † 
22RV1 3 234.0 ± 82.1 * 
LNCaP 3 169.0 ± 32.9 * 
apodox 
PNT1A 6 603.1 ± 256.8 * 
22RV1 5 1344.2 ± 342.4  
LNCaP 5 931.2 ± 274.4  
Lip-8 
PNT1A 4 2076.7 ± 353.6  
22RV1 3 935.3 ± 113.5  
LNCaP 3 729.0 ± 44.1  
myocet 
PNT1A 8 1047.1 ± 279.5  
22RV1 4 1657.1 ± 662.9  
LNCaP 3 1440.0 ± 164.6  
Figure 4. Determination of viability of prostatic cell lines treated with modified forms  
of doxorubicin using MTT assay (A–C); (D) verification of real-time cell impedance-based 
cell growth method (RTCA)-determined IC50 value. Red line indicates theoretical 50% viability. 
No significant difference was observed using one sample t-test. 
 




The aim of this study was to encapsulate doxorubicin into apoferritin and liposomal structures  
and to compare cytotoxic effects caused by newly prepared compounds with commercial ones.  
56 µg/mL of doxorubicin (96.5 µM) was encapsulated into the apoferritin cages. The pH gradient  
method was used to encapsulate higher amount of doxorubicin in lip-8 because the aim was to prepare 
encapsulated doxorubicin in the same simple manner as in the case of commercially produced Myocet. 
Efficiency of doxorubicin entrapment was found to be 56%. Our reached amount of encapsulated 
doxorubicin was thus 19-times higher compared to Simsek et al. [22]. Since apoferritin is stable at the 
physiological pH of 7.4, we suppose that it should not precipitate in blood [23]. 
Liposomal drug delivery systems have recently been greatly investigated to increase the therapeutic 
index of chemotherapy [24]. In our study, a total of 72.4 µM (42 µg/mL) doxorubicin was encapsulated 
into the liposome carrier. Efficiency of doxorubicin entrapment was found to be 42%. In experiments  
of Gokhale et al., 90% encapsulation of doxorubicin was observed [15]. Nevertheless, an average  
IC50 value of 0.27 µM was determined for free doxorubicin in our studied cell cultures. Considering  
the efficiency of encapsulation of 72.4 µM, our encapsulation system can likely deliver effective  
drug amounts for therapeutic applications. Liposomes prepared by us contained 210 µg of doxorubicin  
per micromole of cholesterol. Tseng et al. and Hong et al. achieved concentrations from 110 to 130 µg 
of doxorubicin per micromole of phospholipid [25,26]. 
Cytotoxicities of doxorubicin, epirubicin, apodox (apoferritin filled with doxorubicin), and of  
two liposomal forms of doxorubicin (newly prepared liposome-8 and commercial Myocet) on prostate 
cell lines was compared by using MTT assay and the RTCA system (impedance-based method 
xCELLigence). As demonstrated in our previous studies [27], precise determination of half-maximal 
lethal doses of cytostatics is arduous. Results of assays vary among themselves because methods are 
based on different mechanisms. However, it is not possible to rely solely on the results of one method. 
The main principle of MTT assay is tetrazolium salts’ reduction to formazan by mitochondrial succinate 
dehydrogenase (SDH), which is quantified photometrically. Nevertheless SDH is only active in cells 
with an intact metabolism and respiratory chain. Fasting and oxidative stress, which is present  
by anthracycline treatment, was associated with a significant decrease of SDH activity, and the  
reduction was proportional with the decrease in the amount of SDH total protein [28,29]. Therefore, a false 
reduced viability of MTT assay could be caused by low metabolic activity of cells due to autophagy or 
senescence [30], which are not rare in cytostatic-treated cells. On the other hand, a false reduced or 
increased viability can be also caused by changes in cell size and/or adhesion as determined by RTCA. 
RTCA is based on changes in impedance influenced by cell number, size and adherence thus reference 
methods for accurate cell viability assessment are necessary. The discrepancy between methods is well 
illustrated by relatively low correlation power, as determined by Spearman’s rank correlation in this 
study. In this study, the accuracy of the IC50 determination by these methods was verified by flow 
cytometry (FCM). FCM-determined percentage of propidium-iodide-positive cells correlated with 
RTCA, suggesting that RTCA reflects cellular viability more accurately and that is not biased by 
metabolic status, therefore is more suitable for studies on antineoplastic agents. 
The cytotoxicity determination is in agreement with studies by Graeser et al., showing doxorubicin 
IC50 values 140 nM for LNCaP [31]. As presumed, doxorubicin and epirubicin are significantly the most 
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toxic forms among studied cytostatics. Commercially available doxorubicin forms and those modified 
in our lab are of significantly lower toxicity. Although the toxicity of Myocet is the lowest among  
all of the studied cytostatics, the sensitivity of individual cell types differs significantly. While higher 
toxicity was observed on cell lines derived from non-tumour tissue (PNT1A) and primary tumor 
(22Rv1), the toxic effect on cells derived from metastatic sites (LNCaP) was significantly lower  
in this commercially available modification. These findings indicate a limited efficiency of Myocet  
in the management of advanced disease. 
In contrast, the sensitivity of cell lines to lip-8-dox did show the opposite pattern: although below  
the level of statistical significance, the lowest toxicity was determined for non-tumour PNT1A, toxicity 
to tumorous cell lines was distinctly higher, while the highest toxic effect was observed on a cell line 
derived from secondary tumor—LNCaP. These findings indicate that lip-8-dox is a potential drug  
for the management of advanced cancer. Nevertheless, faster proliferative rate of PNT1A cell line 
compared with a low basal proliferative rate in normal prostatic glands should be taken into account [21]. 
Therefore, we assume that a slowly proliferating non-tumor tissue will be even more resistant compared 
to the cell line model used in this study. The toxicity of the apoferritin-coated doxorubicin synthetized 
in our lab, apodox, was 5-fold lower compared to conventional doxorubicin with no significant 
difference in sensitivity between cell lines. 
Inasmuch as liposome-8 and apodox are less toxic compounds with higher IC50 value, it seems 
possible that different mechanisms could be activated by high and low concentrations of tested 
compounds. It is consistent with the study by Eom et al., who found that chronic exposure of hepatoma 
cells to high doses of doxorubicin induced apoptosis, whereas lower doses induced senescence and  
late death by mitotic catastrophe [32]. It was also demonstrated that low doses of doxorubicin are able  
to induce senescence or autophagy in various types of cells [33,34]. 
4. Experimental Section 
4.1. Chemical and Biochemical Reagents 
Apoferritin from equine spleen, cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) 
sodium salt, HCl, NaOH and water were purchased from Sigma-Aldrich (St. Louis, MO, USA)  
in American chemical society purity. Hydrogenated phosphatidylcholine from soybean was a gift from 
Lipoid GMBH (Ludwigshafen, Germany). Doxorubicin solution 2 mg/mL was obtained from Teva 
Pharmaceuticals (Opava, Czech Republic). To pipette volumes down to micro and nanolitres, pipettes 
used were purchased from Eppendorf Research (Eppendorf, Germany) with the highest certified 
deviation (±12%). The deionized water was prepared using reverse osmosis equipment Aqual 25 (Brno, 
Czech Republic). The deionized water was further purified by using apparatus MiliQ Direct QUV 
equipped with the UV lamp (Millipore, Billerica, MA, USA). The resistance was 18 MΩ. The pH was 
measured using pH meter WTW inoLab (Weilheim, Germany). 
4.2. Preparation of Apoferritin Filled with Doxorubicin 
Apoferritin solution 20 µL (50 mg/mL, equine spleen, Sigma-Aldrich) was diluted with 200 µL  
of ACS water. Doxorubicin (100 µL, 2 mg/mL) was added and mixture was shaken. 1 M HCl (2 µL) 
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was added and turbidity was observed. Fifteen minutes later 1 M NaOH (2.5 µL) was added  
and turbidity disappeared. Solution was subsequently shaken on Vortex Genie2 for 2 h (Scientific 
Industries, Bohemia, NY, USA). Dialyses for 24 h were performed on membrane filter (0.025 µm 
VSWP, Millipore) against 2 L of water. Thus obtained solution was diluted with ACS water to final 
volume of 1 mL. This form is designated as “Apodox”. 
4.3. Preparation of Liposome-8-doxorubicin 
Cholesterol (100 mg), 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (100 mg)  
and phosphatidylcholine (100 mg) were dissolved in chloroform (4.5 mL). A lipid film was obtained  
by rotary evaporation of solvent and residual chloroform was blown out by nitrogen. 
Doxorubicin solution (1 mL, 4 mg/mL) (pH = 7) was added to liposome (20 mg) and shaken for 3 h 
on Vortex. Sample was homogenized with Ultra-Turrax T8 (IKA Werke GmbH, Staufen, Germany)  
for 3 min. The mixture was then heated and shaken for 10 min at 60 °C at Thermomixer Comfort 
(Eppendorf, Germany). Dialyses for 24 h were performed on membrane filter (0.025 µm VSWP, 
Millipore) against 2 L of water. This form is designated as “Lip-8-dox”. 
4.4. Preparation of Myocet, Epirubicin and Doxorubicin 
Myocet was obtained from Cephalon (Maisons-Alfort, France) and the solution of liposome was 
prepared according to the information leaflet. The concentration of doxorubicin was 2 mg/mL. 
Doxorubicin was purchased from Teva Pharmaceuticals (Pardubice, Czech Republic). Epirubicin was 
purchased from EBEWE Arzneimittel GmBH (Unterach, Austria). 
4.5. Cell Cultures 
Three human prostatic cell lines were used in this study: (i) PNT1A human cell line established  
by immortalization of normal adult prostatic epithelial cells by transfection with a plasmid containing 
the SV40 genome with a defective replication origin. The primary culture was obtained from  
the prostate of a 35-year old male at post mortem; (ii) 22Rv1 is a human prostate carcinoma epithelial 
cell line derived from a xenograft that was serially propagated in mice after castration-induced regression 
and relapse of the parental, androgen-dependent CWR22 xenograft. 22Rv1 cells are androgen-receptor 
positive, but its levels are lower compared to the LNCaP cell line. 22Rv1 cells harbor wild-type p53. 
The 22Rv1 cell line is androgen-responsive, yet androgens are not required for growth, although the cell 
line shows growth response in their presence [35]; (iii) The LNCaP cells line was derived from human 
prostate adenocarcinoma cells of a 50-year old Caucasian male in 1977, where cells were taken from  
a needle aspiration biopsy of a metastatic lesion in the left supraclavicular lymph node. Compared  
to that in the 22Rv1 cell line, the androgen receptor of the LNCaP cell line is well expressed,  
cells respond highly to androgens–androgens stimulates cell growth [36]. LNCaP is a wild type  
p53-expressing cell line [35,37]. All cell lines used in this study were purchased from Health Protection 
Agency Culture Collections (Salisbury, UK). 
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4.6. Culture Conditions 
PNT1A, LNCaP, and 22Rv1 cells were cultured in RPMI-1640 medium with 10% FBS. All media 
were supplemented with penicillin (100 U/mL) and streptomycin (0.1 mg/mL), and the cells were 
maintained at 37 °C in a humidified incubator (Sanyo, Japan) with 5% CO2. 
4.7. Treatment of Cells 
Once the cells reached 50%–60% confluence, the growth media were replaced by fresh medium  
for 24 h to synchronize cell growth. The cells were then treated with doxorubicin, epirubicin, Myocet, 
apodox and lip-8-dox with following concentrations used: 0 (control) and 40 µM in fresh medium  
for 48 h. 
4.8. Measurements of Cell Viability—MTT Test 
The suspension of 5000 cells was added to each well of standard microtiter plates. Volume of 200 μL 
was transferred to 2–11 wells. Medium (200 μL) was added to the first and to the last column (1 and 12, 
control). Plates were incubated for 2 days at 37 °C to ensure cell growth. Medium was removed from 
columns 2–11. Columns 3–10 were filled with 200 μL of medium containing increasing concentrations 
of cytostatics (0–40 μM). As control, columns 2 and 11 were filled with fresh medium without 
cytostatics. Plates were incubated for 24; then, media were removed and replaced by a fresh medium, 
three times a day. Columns 1 to 11 were filled with 200 μL of medium containing 50 μL of MTT  
(5 mg/mL in PBS) and incubated in a humidified atmosphere for 4 h at 37 °C, wrapped in aluminium 
foil. After the incubation, MTT-containing medium was replaced by 200 μL of 99.9% dimethyl 
sulphoxide (DMSO) to dissolve MTT-formazan crystals. Then, 25 μL of glycine buffer was added  
to all wells and absorbance was immediately determined at 570 nm (VersaMax microplate reader, 
Molecular Devices, Sunnyvale, CA, USA). All measurements were performed as tetraplicates.  
A macro programmed in Excel (Microsoft Corp., Redmond, WA, USA) was used for the calculation  
of half-maximal inhibition concentration (IC50). Data was fitted with a logistic function to create 
sigmoidal dose-response curve. The curve is described by four variables: upper limit, lower limit, 
skewness of the function and log IC50. The fitting was adjusted using an automated algorithm employing 
a solver function with least squares method. This procedure was used for each repetition and thus 
variance was calculated from these measurements. 
4.9. Cell Proliferation Measurement Using Real-Time Cell-Based Assay 
The real-time cell-based assay (RTCA) xCELLigence (Roche Applied Science and ACEA 
Biosciences, San Diego, CA, USA) consists of four main components: the RTCA analyzer, the RTCA 
station, the RTCA computer with integrated software and disposable E-plate 16. Firstly, the optimal 
seeding concentration for proliferation and cytotoxic assay was determined. After seeding of the total 
number of cells in 200 μL medium to each well in E-plate 16, the attachment, proliferation and spreading  
of the cells was monitored every 15 min. All experiments were carried out for 250 h. The results  
are expressed as relative impedance using the manufacturer’s software (Roche Applied Science  
and ACEA Biosciences). Half-maximal concentration was calculated in the RTCA proprietary  
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software using a sigmoidal dose-response formula and by fitting an area under curve in a time  
period vs. concentration curve type. The precision was derived from multiplicative measurement of  
each concentration. 
4.10. Determination of Viable Cell Numbers by Propidium Iodide Exclusion 
All cells in the culture were harvested and briefly trypsinized and resuspended in PBS. Immediately 
before measurement, propidium iodide was added to a final concentration of 1 µg/mL, and the number 
of viable cells was measured by FACSVerse flow cytometer (BD Biosciences, San Jose, CA, USA).  
The data obtained were analyzed using FACSuite software (BD Biosciences). 
4.11. Determination of Liposomal Particle Size 
The average size of the nanoparticles and the size distribution were determined by quasielastic laser 
light scattering with a Malvern Zetasizer (NANO-ZS, Malvern Instruments Ltd., Worcestershire, UK). 
1.0 mL of water solution of liposome was put into a polystyrene latex cell and measured at a detector 
angle of 173°, a wavelength of 633 nm, a refractive index of 0.30, a real refractive index of 1.59,  
and a temperature of 25 °C. 
4.12. Determination of Cholesterol 
Content of cholesterol was determined by absorbance measurement at 505 nm using reagent R1 
(Greiner, Frickenhausen, Germany). The measurements are based on our previous experiments [38]. 
4.13. Spectrophotometric Measurements 
Fluorescence and absorption spectra were acquired by multifunctional microplate reader Tecan 
Infinite 200 PRO (Tecan, Männedorf, Switzerland). The excitation wavelength used was 490 nm  
and the fluorescence scan was measured within the range from 530 to 850 nm per 2-nm steps.  
The detector gain was set to 90. The samples were placed in a UV-transparent 96-well microplate  
with a flat bottom by CoStar (Corning, New York, NY, USA). To each well 100 μL of sample was 
placed. All measurements were performed at 30 °C controlled by Tecan Infinite 200 PRO (Tecan,  
Männedorf, Switzerland). 
4.14. Scanning Electron Microscope (SEM) 
Structure of liposomes were characterised by an electron microscope (SEM). For documentation  
of the selected nanomaterials, a FEG-SEM MIRA XMU instrument (Tescan, a.s, Brno, Czech Republic) 
was used. 
4.15. Difference Pulse Voltammetry 
The three-electrode system consisted of glassy carbon working electrode, an Ag/AgCl/3 M KCl 
reference electrode and a platinum electrode acting as the auxiliary was used. Settings of the potentiostat 
were as it follows: scan from −0.3 to −0.9 V using an amplitude of 25 mV, step of 2 mV and frequency 
Int. J. Mol. Sci. 2014, 15 22974 
 
 
of 25 Hz; equilibration time 20 s; nitrogen bubbling during the experiment; cleaning at −1.0 V for 40 s; 
and stirring during cleaning step. 
4.16. Statistical Analysis 
The half-maximal inhibition concentrations (IC50) of individual cytostatics from MTT tests were 
calculated from sigmoidal dose-response-fitted data. Half-maximal concentration from impedance-based 
measurement was calculated in software supplied by manufacturer (RTCA 1.2.1). Data was tested  
for normality using distribution fitting and chi-squared test. Factorial ANOVA was used to compare the 
effect of individual factors—cell line, cytostatic, and method used (MTT- and impedance-based). When 
significant difference was determined, Bonferroni post hoc test was used. p-level < 0.05 was considered 
significant. Software Statistica (StatSoft, Tulsa, OK, USA) was used for analyses. 
5. Conclusions 
This study focused on comparison of toxicity of novel modified forms of doxorubicin prepared in our 
lab. Despite the differences between assays, doxorubicin was the most toxic of tested compounds. This 
study confirmed lower toxicity of commercially available Myocet and also of modifications prepared in 
our lab—apoferritin-coated apodox and liposome-coated lip-8-dox, which complies with the initial 
premise. Most importantly, it was demonstrated, that liposomal modification “lip-8-dox” exhibits higher 
toxicity to tumorous cell lines, but is significantly less toxic for non-tumour cells. Based on this pilot 
study, precise mechanisms of coated doxorubicin modifications and their effects on in vivo models will 
be the subject of future experiments. 
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